ReviewCurrent pharmaceutical design2015
Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis.
Review in Current pharmaceutical design, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 14 citations in OpenAlex.
- Evaluation of the Functional Suitability of Carboxylate ChlorinPharmaceutics · 2025Article
- Nanotheranostics: A Cutting-edge Technology for Cancer Management.Current pharmaceutical biotechnology · 2025Review
- Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Molecular Imaging and Non-molecular Imaging of Atherosclerotic Plaque Thrombosis.Frontiers in cardiovascular medicine · 2021Review
- Chemokine receptors: Key for molecular imaging of inflammation in atherosclerosis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Assessment of Targeted Nanoparticle Assemblies for Atherosclerosis Imaging with Positron Emission Tomography and Potential for Clinical Translation.ACS applied materials & interfaces · 2019Article
- Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics.ACS nano · 2018Review
- Magnetic Resonance Imaging of Atherosclerotic Plaque at Clinically Relevant Field Strengths (1T) by Targeting the Integrin α4β1.Scientific reports · 2018Article
- Use of Nanoparticle Contrast Agents for Cell Tracking with Computed Tomography.Bioconjugate chemistry · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Atherosclerosis is a systemic disease characterized by the development of multifocal plaque lesions within vessel walls and extending into the vascular lumen. The disease takes decades to develop symptomatic lesions, affording opportunities for accurate detection of plaque progression, analysis of risk factors responsible for clinical events, and planning personalized treatment. Of the available molecular imaging modalities, radionuclidebased imaging strategies have been favored due to their sensitivity, quantitative detection and pathways for translational research. This review summarizes recent advances of radiolabeled small molecules, peptides, antibodies and nanoparticles for atherosclerotic plaque imaging during disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.